[(2R,3R,4S,5R,6R)-6-[2-Chloro-1-[[(2S,4R)-1-Methyl-4-Propyl-Pyrrolidine-2-Carbonyl]Amino]Propyl]-4,5-Dihydroxy-2-Methylsulfanyl-Tetrahydropyran-3-Yl] Dihydrogen Phosphate

Production-scale preparation of clindamycin phosphate injection—whether configured as a ready-to-use solution or a lyophilised cake for reconstitution—demands rigorous control over hydrolytic degradation pathways that accelerate sharply outside a pH window of 5.5 to 6.5. In a standard batch of 150 mg/mL (as clindamycin) solution product, the active ingredient is charged at approximately 178.5 mg/mL of clindamycin phosphate, equivalent to 1.2 g per 1 g of clindamycin base, dispersed in Water for Injection (WFI) that has been stripped of dissolved oxygen by nitrogen sparging. The compounding vessel, typically a 500 L 316L stainless-steel tank with electropolished surfaces (Ra ≤ 0.5 µm), is operated under closed-system transfer to maintain Grade A / ISO 5 environmental quality according to EU GMP Annex 1. pH adjustment is performed with diluted hydrochloric acid or sodium hydroxide while monitoring conductivity and temperature; excursions below pH 4.8 during pH cycling are documented to elevate free clindamycin base above the ICH Q3B identification threshold within 8 hours at 25°C, driven by acid-catalysed cleavage of the phosphoester bond. The bulk solution is then circulated through 0.45 µm polyethersulfone pre-filters and two serial 0.22 µm PVDF sterilising-grade cartridges (typically 10-inch capsules with an effective filtration area of 0.7 m²) before aseptic filling into Type I glass vials under a unidirectional airflow of 0.45 m/s. For solution injections, vials are filled to target volume and stoppered without terminal steam sterilisation, since autoclaving at 121°C for even 8 minutes (F₀ ≈ 4) has been observed in forced degradation studies to generate lincomycin-2-phosphate and other unspecified degradation products exceeding 0.2%; therefore, sterility assurance relies entirely on the validated filtration train and glove-port integrity testing. Lyophilised presentations, such as 300 mg per vial Clindamycin Phosphate for Injection, are filled at a concentration of 300 mg clindamycin phosphate per 2 mL fill volume and subjected to a freeze-drying cycle in a production-scale lyophiliser (shelf area 22 m²), with primary drying at a shelf temperature of −25°C and chamber pressure of 200 µbar to avoid collapse temperature (−18°C for this formulation) and secondary drying ramping to +35°C over 18 hours. Finished product specifications reference USP monograph Clindamycin Phosphate Injection and EP 01/2025:0581, with assay limits of 90.0–110.0% of labelled clindamycin, endotoxin ≤ 0.58 EU/mg, and particulate matter complying with USP <788>.

Dermal Formulation Engineering: Carbomer Rheology and Preservative Efficacy

Manufacture of a 1.0% w/w clindamycin phosphate topical gel, equivalent to approximately 0.83% clindamycin base, is executed by first swelling Carbomer 940 (typical loading 1.2–1.5% w/w) in purified water within a planetary disperser equipped with a wall-scraper anchor and a high-speed rotor-stator head operating at 1,500 rpm. The clindamycin phosphate is pre-dissolved in a co-solvent mixture of ethanol (25–30% w/w) and propylene glycol (8–12% w/w) that has been adjusted to pH 5.0 with sodium hydroxide; adding the active in this phase reduces contact time with the acidic carbomer dispersion, which prior to neutralisation can exhibit pH as low as 2.9 and trigger premature hydrolysis. Once homogeneous, the two phases are combined under low shear, and triethanolamine is metered in to raise the final formulation pH to 5.5–6.0, a range at which carbopol constructs a clear, electrostatically stabilised gel network with a yield stress of 35–50 Pa at 25°C. The filled primary container is typically an aluminium tube with an internal epoxy-phenolic lacquer or a laminated polyethylene/aluminium/polyethylene barrier tube, selected because clindamycin phosphate exhibits a photolytic N-demethylation pathway when exposed to UV-A radiation; ICH Q1B photostability testing demonstrates a 4.2% loss of potency within 8 hours of direct sunlight equivalent irradiation unless opaque packaging is employed. For multi-use containers, preservative efficacy testing per USP <51> must demonstrate a 3-log reduction of Staphylococcus aureus within 14 days, and the chosen preservative system—often a combination of benzyl alcohol at 0.5% v/v and methylparaben—must be validated for compatibility, as benzyl alcohol can partition into the carbomer phase and reduce free concentration below the minimum inhibitory concentration (0.5%). The downstream filling line operates at 60 tubes/min with inline viscosity checks using a process viscometer set to alarm at values outside 40,000–80,000 cP; any batch failing to meet the acceptable range is diverted for rework, which is complicated because high-shear re-dispersion can irreversibly break the carbomer microgel structure and permanently lower viscosity. Final product release conforms to the requirements of a US FDA NDA such as NDA 050537 (Cleocin T), including residual monomeric methacrylic acid ≤ 0.25% and microbial limits per USP <61> and <62> for non-sterile topicals.

Can Benzoyl Peroxide and Clindamycin Phosphate Coexist in a Single Phase?

When a clindamycin phosphate concentration of 1.2% w/w is co-formulated with benzoyl peroxide (BPO) at 5.0% w/w as in Duac Gel (NDA050756), thermodynamic incompatibility mandates a dual-chamber delivery system rather than a true single-phase product. Benzoyl peroxide, a strong oxidizing agent with a standard reduction potential of approximately −0.75 V versus SCE, attacks the 2-methylsulfanyl substituent on the tetrahydropyran ring and the electron-rich pyrrolidine nitrogen, accelerating degradation; forced degradation studies at 40°C/75%RH indicate that in a premixed gel, clindamycin phosphate purity drops to 85% within 4 weeks, whereas the separated phases maintain >97% potency for 24 months. Manufacturing therefore splits the product into two distinct bulk intermediates: the clindamycin phosphate aqueous gel phase is prepared at pH 5.8 using hydroxypropylcellulose as the rheology modifier, while the BPO phase employs a low-pH (3.5–4.0) carbomer gel to stabilise the peroxide. Filling is executed on a specialized two-stream positive-displacement pump fed by independent 500 L tanks, delivering both phases simultaneously into the same multi-layer tube without internal mixing; the nozzle design ensures co-extrusion with a 1:1 volume ratio, forming a side-by-side ribbon that the patient mixes manually on the fingertips immediately before application. Process analytical technology monitors the fill volume with a ±3% tolerance per side, since disproportionate dispensing alters the final BPO concentration and shifts the bactericidal spectrum; a deviation of 0.5% absolute BPO can raise the minimum inhibitory concentration against Cutibacterium acnes from 0.12 µg/mL to 0.25 µg/mL as measured by broth microdilution per CLSI M11-A8. Regulatory compliance also demands adherence to ICH Q1A(R2) stability commitment batches stored in inverted orientations to simulate patient use, and the specification for free phosphate, a hydrolysis marker, must not exceed 1.5% at shelf life.

Veterinary parenteral formulations of clindamycin phosphate are administered primarily to dogs and cats for soft-tissue infections, osteomyelitis, and dental abscesses at a labelled concentration of 25 mg/mL (as clindamycin) in multi-dose vials, which necessitates inclusion of benzyl alcohol at 0.9% v/v as a bacteriostatic agent. The batch formula charges 30 mg/mL of clindamycin phosphate to account for a 3% overage that compensates for adsorption losses on inline filter media and tubing surfaces, a value confirmed by recovery studies using silicone and PTFE fluid paths over a 4-hour hold. Compounding is performed in a 200 L steam-in-place vessel under Grade C background with Grade A local protection, maintaining precisely the same pH-versus-temperature control boundaries as human injectable manufacture, because clinical toxicology data in Beagle dogs indicate that the lincomycin-related impurity clindamycin-3-phosphate, which forms more rapidly below pH 4.6, carries a reduced safety margin in canines relative to humans. Sterile filtration proceeds through double-layer 0.22 µm hydrophobic PTFE filter cartridges validated with Brevundimonas diminuta challenge at 10⁷ CFU/cm², and aseptic filling into Type II glass vials is conducted on a 12-head rotary piston filler operating at 120 vials/min. Release testing follows VICH GL18 and the relevant EU veterinary monograph, with batch certification requiring absence of Salmonella and E. coli in the raw material, a specification not required for human-grade API sourced under a Certificate of Suitability, but mandatory for veterinary-only supply chains. Field pharmacovigilance data collected from 1,500 canine administrations recorded a 1.8% incidence of sterile abscess at the injection site when the pH of the solution drifted above 7.0 due to improper neutralisation, underscoring the in-process requirement for automatic pH-controlled acid addition with a deadband of ±0.05 units.

Sterile Compounding of Intravenous Admixtures in ISO Class 5 Environments

Hospital pharmacy admixture of clindamycin phosphate intravenous infusions from either an approved injection concentrate or a lyophilised powder involves dilution into 0.9% sodium chloride injection or 5% dextrose injection to a final concentration ranging from 6 mg/mL to 12 mg/mL (as clindamycin), and must be carried out inside an ISO 5 horizontal laminar airflow hood or a biological safety cabinet compliant with USP <797>. The compatibility of the infusion container material—polyvinyl chloride (PVC) or non-PVC polyolefin—with clindamycin phosphate has been systematically evaluated: in PVC bags plasticised with di-2-ethylhexyl phthalate (DEHP), no significant sorption was detected over 24 hours at 23°C, but in polypropylene syringes, a 2.3% decline in aggregate peak area was observed after 8 hours when stored at 30°C, presumed due to surface adsorption on the hydrocarbon polymer. Physical incompatibility is most consequential for the prescriber; co-administration of clindamycin phosphate with aminophylline, ampicillin sodium, phenytoin sodium, or magnesium sulfate results in immediate visible precipitation when combined in the same line without adequate flushing, owing to pH shift beyond the 5.0–7.0 stable solubility zone or formation of poorly soluble ion pairs between the anionic phosphate moiety and divalent cations. A y-site simulation study using a 1:1 v/v ratio published in the Handbook on Injectable Drugs lists 47 drugs as physically incompatible at the concentrations tested, a fact that necessitates dedicated IV lines and a minimum flush volume of 20 mL of compatible diluent between administrations. The beyond-use date assigned per USP <797> for a medium-risk compounding scenario is 30 hours under refrigeration (2–8°C), justified by dynamic light scattering monitoring that detects nanoparticle aggregates exceeding 1 µm after 36 hours, which would be rejected by the in-line 0.22 µm filter recommended for infusion.

Active Pharmaceutical Ingredient Characterisation for Bioequivalence Lot Selection

Reference-listed drug applications and abbreviated new drug applications for clindamycin phosphate dosage forms depend upon the selection of an API batch whose particle size distribution, crystallinity, and impurity profile mirror the originator’s drug master file. A typical DMF-reviewed clindamycin phosphate lot exhibits a D₁₀ of 5 µm, D₅₀ of 28 µm, and D₉₀ of 65 µm as measured by laser diffraction (Malvern Mastersizer 3000, dry dispersion), and orthogonal confirmation of form II polymorph via X-ray powder diffraction with characteristic peaks at 2θ = 10.4°, 14.8°, and 21.3°. Deviations in particle morphology, particularly the presence of agglomerates > 90 µm formed during ambient humidity exposure above 60% RH, retard dissolution in the intrinsic dissolution apparatus (USP <1087>), with an intrinsic dissolution rate dropping from 0.42 mg/min/cm² to 0.28 mg/min/cm² when D₉₀ shifts to 105 µm—a change sufficient to fail an f2 similarity factor comparison in a pilot bioequivalence study. Process engineering at the API finishing stage therefore applies fluidised-bed milling with an in-line classifier wheel set to 12,000 rpm, yielding a target span of 1.4, and subsequent drying to a water content below 2.0% KF. Quality control sampling per ICH Q7A includes HPLC quantification of specified impurities: lincomycin ≤ 0.1%, clindamycin-3-phosphate ≤ 0.5%, and any unspecified single impurity ≤ 0.10%, using a C18 column (250 × 4.6 mm, 5 µm) with phosphate buffer pH 6.0 and acetonitrile gradient at 1.0 mL/min. These API specifications directly anchor the downstream formulation critical quality attributes and are referenced in the ANDA module 3.2.S.4 section on control of drug substance, with full traceability to USP Clindamycin Phosphate RS lot standards.